Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for AORT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 9.055M
March 31, 2026 8.841M
December 31, 2025 9.122M
September 30, 2025 8.078M
June 30, 2025 7.063M
March 31, 2025 6.728M
December 31, 2024 7.404M
September 30, 2024 6.605M
June 30, 2024 7.497M
March 31, 2024 6.946M
December 31, 2023 7.645M
September 30, 2023 6.421M
June 30, 2023 7.418M
March 31, 2023 7.223M
December 31, 2022 8.304M
September 30, 2022 11.80M
June 30, 2022 8.648M
March 31, 2022 10.13M
December 31, 2021 9.46M
September 30, 2021 9.972M
June 30, 2021 8.36M
March 31, 2021 7.754M
December 31, 2020 6.574M
September 30, 2020 5.755M
June 30, 2020 5.522M
Date Value
March 31, 2020 6.356M
December 31, 2019 5.312M
September 30, 2019 6.259M
June 30, 2019 5.841M
March 31, 2019 5.548M
December 31, 2018 6.784M
September 30, 2018 5.225M
June 30, 2018 5.719M
March 31, 2018 5.37M
December 31, 2017 6.363M
September 30, 2017 4.277M
June 30, 2017 4.728M
March 31, 2017 4.093M
December 31, 2016 3.844M
September 30, 2016 3.714M
June 30, 2016 3.279M
March 31, 2016 2.609M
December 31, 2015 2.54M
September 30, 2015 2.96M
June 30, 2015 2.684M
March 31, 2015 2.252M
December 31, 2014 2.092M
September 30, 2014 1.902M
June 30, 2014 2.203M
March 31, 2014 2.502M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Alphatec Holdings, Inc. 18.17M
Globus Medical, Inc. 36.32M
Glaukos Corp. 51.30M
TransMedics Group, Inc. 31.63M
PROCEPT BioRobotics Corp. 20.10M